HIND Company Profile and Key Details

Vyome Holdings, Inc. generated EPS of -$177.38 over the past year. Five-year average earnings growth is 80.05%. Wall Street analysts project EPS growth of 90.07% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $15.00. The high target offers 588.07% upside. The low target suggests 588.07% downside. The mean target is $15.00. This offers 588.07% upside. Vyome Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -16.67%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -49.86% in August 14, 2024.

HIND has shown weak momentum, losing -14.55% over the past week and -47.73% over the past quarter, though year-to-date performance is down -19.77%. Short-term trend indicators are bullishly aligned (SMA20 27.93%, SMA50 9.5%, SMA200 -57.44%). The stock’s 14-day RSI is 59.6 (neutral), while the ATR of 0.35 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.9% below its high and over 92.0% above its low. Average 10-day trading volume of 12.85 thousand shares is below the 3-month average of 25.40 thousand, indicating normal recent market interest.

Vyome Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.07. This means the shares are trading above this model’s fair value.

Vyome Holdings, Inc. (NASDAQ:HIND) closed at $2.20 USD, gaining $0.02 (0.92%) from the previous close of $2.18. The stock is currently mid-range between its 52-week high and low $1.75 and $18.60. With a market capitalization of about $12.39 million, Vyome Holdings, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.50). Key stats such as the average daily volume over the past year has been around 26.02 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Vyome Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Venkateswarlu Nelabhotla, the company employs approximately 18 people and listed since October 06, 2016. Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders.

Our AI price prediction model suggests that Vyome Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.92%, with price expected at $2.20 by August 04, 2026, within a range of $2.13 to $2.26 3-Month Outlook: Projected fall of -86.7%, reaching $0.29 by October 19, 2026, with a range of $0.20 to $0.36. 1-Year Outlook: Projected gain of 21.1%, with price at $2.64 by July 21, 2027, within a range of $1.51 to $2.76.

Vyome Holdings, Inc. (NASDAQ:HIND) shares are down -19.77% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Vyome Holdings, Inc. trading at a premium to the broader market with a P/E of -0.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.00, suggesting 588.07% upside. Our AI forecast model points to short-term strength (0.92% over two weeks), a medium-term fall (-86.7% over three months), and a longer-term gain (21.1% over one year), with expected trading ranges indicating moderate volatility.

Vyome Holdings, Inc. trades at a P/E ratio of -0.06, slightly below the S&P 500 average, with a price-to-sales ratio of 9.04 and a price-to-book ratio of 1.9 suggesting the stock is closer to book value. The P/FCF stands at -3.97, also above market averages.